Search Results
Your search for ,aLl matches 18304 pages
Showing 16451 - 16500ASCO Asks CMS to Revisit Its Payment Policy to Support Optimal Cancer Care
ASCO has called on the Centers for Medicare & Medicaid Services (CMS) to reconsider revisions to payment policies that could be administratively burdensome to oncology practices and result in reimbursement that inadequately supports optimal cancer patient care. In a comment letter to CMS on...
Be a Voice in The Campaign to Conquer Cancer
We'll provide the resources. You provide the voice. The Campaign to Conquer Cancer is raising $150 million to support a world free from the fear of cancer. Our potential to raise money increases with every new person who learns about our work. We need the most trusted leaders in the oncology...
ASCO, ACS, ASTRO Study Finds Increased Travel Distance Affects Whether Patients Receive Adjuvant Chemotherapy
A new study conducted by ASCO in collaboration with the American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) and published in the Journal of Clinical Oncology1 found that patients who have to travel farther to appointments are less likely to receive adjuvant...
Updated Resource for Your Patients: Advanced Cancer Care Planning Booklet
The latest version of ASCO Answers Advanced Cancer Care Planning is now available. This booklet contains comprehensive information about how patients can communicate directly and honestly about advanced cancer and end-of-life care with friends, family, children, and the health-care team. This...
Journal of Oncology Practice to Expand in 2016: New Section Dedicated to Practical, Authoritative Clinical Reviews
In early 2016, readers of Journal of Oncology Practice (JOP) will be greeted with an expanded journal, featuring a new section of succinct, focused, practical clinical reviews authored by expert opinion leaders in oncology. These reviews are designed to provide busy, full-time clinicians with...
Focus on Geriatric Oncology: ASCO Prepares for an Aging Nation
The United States—and much of the world—is experiencing unprecedented demographic shifts in the population of older people, defined as people age 65 and over. In 2012, the population of older people in the United States reached a never-before seen height of 43.1 million, a number that will more...
Increased Risk of Death From Breast Cancer for Women With Ductal Carcinoma in Situ vs General Population
In a study reported in JAMA Oncology, Steven A. Narod, MD, FRCPC, of Women’s College Research Institute, Women’s College Hospital, and the University of Toronto, and colleagues found that the risk of breast cancer mortality was elevated in patients with ductal carcinoma in situ compared with the...
Older Patients With Cancer: A Growing Population in Need of Evidence-Based Care
The 2013 Institute of Medicine (IOM) report Delivering High Quality Cancer Care: Charting a New Course for a System in Crisis1 identified the dearth of evidence on older adults as a major quality-of-care issue. The U.S. population is aging at a rapid rate, and cancer is a disease that primarily...
ASCO Statement: Improving the Evidence Base for Treating Older Adults With Cancer
Older persons are the fastest-growing segment of the U.S. population and account for the majority of cancer diagnoses and deaths and the majority of cancer survivors. However, since this population is underrepresented in clinical trials, the evidence base for treating older patients is poor. As...
Docetaxel Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney et al reported on the results of a seminal phase III trial (E3805) of chemohormonal therapy vs androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer in a recent issue of The New England Journal of Medicine,1 and the study is summarized in this issue of The ASCO Post....
Adding Docetaxel to Androgen-Deprivation Therapy Prolongs Overall Survival in Metastatic Prostate Cancer
In a phase III trial (E3805) reported in The New England Journal of Medicine, Christopher J. Sweeney, MBBS, of Dana-Farber Cancer Institute, Boston, and colleagues found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median...
Male Breast Cancer: An Understudied Disease and Clinical Challenge
Male breast cancer is an uncommon disease, although the incidence has increased over the past couple of decades. As with many other “orphan” diseases, male breast cancer is understudied, especially in randomized controlled trials. Although it shares similarities with female breast cancer, some...
Adjuvant Treatment of Early-Stage Breast Cancer: Meta-analyses Provide More Clarity
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) continues its practice of being a lighthouse, shedding its beacon of light on the vast ocean of breast cancer research through the publication of two large, individual patient level–data meta-analyses on the management of women with...
EBCTCG Meta-analyses Show Improved Outcomes With Aromatase Inhibitors vs Tamoxifen and a Potential Benefit of Adjuvant Bisphosphonates Limited to Postmenopausal Women
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) patient-level meta-analyses, concurrently reported in The Lancet, sought to clarify the effects of adjuvant aromatase inhibitor vs tamoxifen treatment and adjuvant bisphosphonate treatment in early breast cancer.1,2 The endocrine...
Bridging the Gap Between Pediatric and Adult Oncology Care
According to the National Cancer Institute (NCI), about 70,000 adolescents and young adults—defined by the NCI as those in the 15- to 39-year-old range—are diagnosed with cancer each year in the United States, about six times the number of cases diagnosed in children aged 0 to 14.1 And, although...
Better Definitions and Biomarkers Needed to Reduce Cancer Overdiagnosis
At the third annual Preventing Overdiagnosis Conference, speakers described the prevalence and consequences of overdiagnosis in several medical specialties, including cancer. The Conference, which had the theme “Winding Back the Harms of Too Much Medicine,” was co-sponsored by the National Cancer...
MMRF Announces Enrollment Completion of CoMMpass Study
The Multiple Myeloma Research Foundation (MMRF) announced that the MMRF CoMMpass StudySM, the most comprehensive long-term genomic study ever conducted in myeloma, has reached full enrollment, with 1,000 patients now participating. The global study is mapping the genomic profile of each enrolled...
Clinical Implications of Survivorship Study Findings
Based on study findings presented at the 2015 ASCO Annual Meeting, Arif Kamal, MD, MHS, of Duke University, Durham, North Carolina, listed six points for clinicians to consider that could change practice now or in the near future for cancer survivors. “Drugs for cancer cachexia are on their...
Patient and Survivor Care Studies Yield Useful Results to Improve Quality of Life
Recent studies have yielded useful results that clinicians can put into practice, some right now, to help improve the quality of life for patients with cancer. Concerns addressed included cachexia, pain, “chemobrain,” and fertility preservation. At the Best of ASCO®/Chicago meeting, Arif Kamal,...
Nivolumab in Lung Cancer Supported by Updated Trial Data
For the treatment of advanced squamous non–small cell lung cancer (NSCLC), the programmed cell death protein 1 (PD-1) antibody nivolumab (Opdivo) continues to show results in key trials that now report 18-month data. The updates were reported at the 16th World Conference on Lung Cancer in Denver,...
Lung Cancer Rates Doubling Among Nonsmokers
Lung cancer is becoming an equal-opportunity malignancy—with rates rising among never-smokers, especially females, according to studies presented at the 16th World Conference on Lung Cancer in Denver. British investigators reported that in one large tertiary medical center, the proportion of...
Expert Point of View: Martin Reck, MD, PhD
Martin Reck, MD, PhD, of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf in Germany, discussed the studies. In pretreated patients, he said, “We have seen confirmed efficacy” [for AZD9291] and “impressive activity.” In the first-line setting, its efficacy is still being...
AZD9291 Updates Encouraging for Treatment-Resistant NSCLC
At the 16th World Conference on Lung Cancer, several studies showed consistent activity with the investigational third-generation inhibitor AZD9291 in patients with advanced non–small cell lung cancer (NSCLC) that is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors....
Ductal Carcinoma in Situ: Where We Have Been and Where We Can Be
Ductal carcinoma in situ has been a recent topic of debate in the news because of a recent article by Narod et al1 and an accompanying editorial2 about the study in JAMA Oncology. This study, summarized in this issue of The ASCO Post, chronicled the long-term outcomes for women diagnosed with...
NCCN Turns 20: Value-Based Care Has Arrived
Twenty years ago, the National Comprehensive Cancer Network (NCCN) began as a cooperative effort of 12 prestigious cancer centers, working to define and promote national guidelines for the care of patients with cancer. A major goal was to encourage uniformity in the management of malignant...
EGFR Gene Copy Number as Biomarker for Antibody Treatment in Squamous Cell NSCLC
Two studies presented at the 16th World Conference on Lung Cancer suggest that high expression of the epidermal growth factor receptor (EGFR), or gene copy number, may indicate potential benefit from EGFR antibodies in squamous cell non–small cell lung cancer (NSCLC). The studies were presented by...
What Do You Say When She Is No Longer Living With Cancer?
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Patients Whose Treatment Included Bevacizumab Were More Likely to Experience Toxicity but Less Likely to Be Hospitalized
A study among patients with advanced non–small cell lung cancer (NSCLC) treated with carboplatin-paclitaxel or carboplatin-paclitaxel-bevacizumab (Avastin) found that those receiving the triplet were more likely to experience a toxicity event but less likely to be hospitalized within 180 days after ...
UC Davis Granted $15.5 Million to Build World’s First Total-Body PET Scanner
A University of California, Davis research team has been awarded $15.5 million to build the world’s first total-body positron emission tomography (PET) scanner, which could fundamentally change the way cancers are tracked and treated. The Transformative Research Award, part of the National...
Important Caveats to Consider Concerning Low-Dose Daily Aspirin for the Primary Prevention of Colorectal Cancer
The use of low-dose aspirin by most adults aged 50 to 59 for the primary prevention of colorectal cancer is now included in the U.S. Preventive Services Task Force (USPSTF) updated draft recommendation statement, “Aspirin to Prevent Cardiovascular Disease and Cancer.”1 The release of the statement...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
The Race of My Life
I've lived my adult life by three guiding principles I learned as an adventure racer: to set goals, to determine how to achieve them, and to persevere in the face of adversity. Those standards helped me complete more than 70 marathons and 7 Ironman competitions, and they helped me conquer breast...
American Cancer Society Awards 2015 Medals of Honor
The American Cancer Society has bestowed its highest honor on four individuals and one foundation during the Society’s 2015 Medal of Honor ceremony and celebration dinner in Washington, DC. The Medal of Honor is awarded to those who have made the most valuable contributions and impact in the fight...
Clinical Trials Actively Recruiting Patients With Breast Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with breast cancer. The trials are investigating cancer risk based on breast density; novel imaging techniques; fasting and chemotherapy; radiosurgery; lymph node dissection; ...
A Snapshot of Early Immunotherapy
Over the past several years, immunotherapy has had a renaissance of sorts, emerging as one of the most active areas in cancer research. For instance, we have seen the therapeutic promise of disrupting the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) immune checkpoints in cancer,...
Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Question 1: What is the most likely diagnosis for this patient? Correct Answer: B. Primary central nervous system lymphoma. Expert Perspective In an immunocompetent host, the differential diagnosis of isolated or multiple brain lesion(s) includes autoimmune etiologies such as neurosarcoidosis,...
$12 Million Multi-institutional SPORE Grant to Focus on Mutations in the NF1 Gene
A new, multi-institution research endeavor brings together scientists from nine leading institutions to find treatments for a group of rare cancers, all caused by a particular gene mutation. The researchers won a 5-year, $12 million grant through the National Cancer Institute’s (NCI) competitive...
Early Research of David G. Nathan, MD, Ushered in the Field of Pediatric Hematology
When David G. Nathan, MD, was admitted to Harvard University in 1947, he had every intention of becoming an English professor. It was only his lack of writing talent that dissuaded him from a life in the classroom and propelled him into a medical career that has spanned more than 5 decades and has...
Confessions of a Neurosurgeon
BookmarkTitle: Do No Harm: Stories of Life, Death, and Brain SurgeryAuthor: Henry Marsh, CBE, FRCSPublisher: Thomas Dunne BooksPublication date: May 26, 2015Price: $25.99, hardcover; 288 pages “I often have to cut into the brain and it is something I hate doing. With a pair of diathermy forceps I ...
A Neurologist’s Life: Oliver Sacks, MD
BookmarkTitle: On the Move: A LifeAuthor: Oliver Sacks, MDPublisher: Alfred A. KnopfPublication date: April 28, 2015Price: $27.95, hardcover; 416 pages Our ability to detect cancer has grown markedly over the past several decades, with the advent of more sensitive screening methods, new...
Pain, Still Undertreated and Misunderstood
Bookmark Title: A Nation in Pain: Healing Our Biggest Health ProblemAuthor: Judy ForemanPublisher: Oxford University PressPublication date: May 1, 2015Price: $19.95, paperback; 464 pages The subject of pain has been written about extensively, from the intriguing sociopolitical history of opium to...
Glimpses of the Human Condition Through Lively, Medically Themed Short Stories
BookmarkTitle: A View From the Inside: A Collection of Medically Oriented Short StoriesAuthor: Augustine L. Perrotta, DOPublisher: Keith Publications, LLCPublication date: March 31, 2015Price: $14.95, paperback; 246 pages The field of medicine, ripe with dramatic tension, offers an endless array...
Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 22, 2015, trifluridine/tipiracil (Lonsurf) was...
Michael Reney, MBA, Named CFO at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has named Michael Reney, MBA, its Chief Financial Officer (CFO), where he will be responsible for all financial operations, including accounts payable, financial planning and reporting, payroll, capital asset management, tax, and general and patient accounting....
Addition of Bevacizumab to Standard Chemotherapy Improves Overall Survival Only in High-Risk Ovarian Cancer
Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Amit M. Oza, MD, and colleagues indicate no significant improvement with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer.1 However, an overall...
Anti-EGFR Therapy in Squamous Cell Lung Carcinoma: Swimming With or Against the Tide?
Lung cancer is the most common, lethal, and costly cancer worldwide, accounting for at least 1.8 million new cases per year (12.9% of the total).1 Over the past decade, there has been a major shift in the treatment of non–small cell lung cancer (NSCLC), especially in adenocarcinoma, accompanied by...
Addition of Necitumumab to First-Line Gemcitabine/Cisplatin Improves Overall Survival in Stage IV Squamous NSCLC
In the phase III SQUIRE trial reported in The Lancet Oncology, Nick Thatcher, PhD, FRCP, of The Christie Hospital NHS Trust, Manchester, UK, and colleagues found that the addition of the second-generation epidermal growth factor receptor (EGFR) antibody necitumumab to first-line...
Pembrolizumab in Previously Treated PD-L1–Positive Metastatic NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 2, 2015, the U.S. Food and Drug Administration granted...
Three Young Investigators Named Winners of 2015 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSKCC) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Bradley E. Bernstein, MD,...
Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 30, 2015, the U.S. Food and Drug Administration...
